Compare
Cryo Cell International Inc vs Viemed Healthcare, Inc. vs Progyny, Inc. vs BioRestorative Therapies, Inc.
| Latest fiscal year | Cryo Cell International Inc CCEL | Viemed Healthcare, Inc. VMD | Progyny, Inc. PGNY | BioRestorative Therapies, Inc. BRTX |
|---|---|---|---|---|
| Year ended | 2025-11-30 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $31.57M | $270.28M | $1.29B | $359.7K |
| Revenue growth (YoY) | -1.3% | +20.5% | +10.4% | -10.3% |
| Gross margin | 76.6% (computed) | 57.5% | 23.6% | 93.4% |
| Operating margin | 1.5% | 8.5% | 6.6% | n/m |
| Net margin | -7.7% | 5.5% | 4.5% | n/m |
| Net income | -$2.43M | $14.93M | $58.52M | -$14.24M |
| EPS (Diluted) | -$0.30 | $0.37 | $0.65 | -$1.58 |
| Operating cash flow | $5.48M | $51.92M | $210.19M | -$10.79M |
| Free cash flow | $5.25M | $11.93M | $191.78M | -$10.91M |
| Cash & equivalents | $319.0K | $13.50M | $112.24M | $1.51M |
| Total assets | $61.73M | $199.15M | $742.43M | $4.08M |
| Total liabilities | $80.33M | $55.63M | $226.39M | n/a |
| Shareholders' equity | -$18.61M | $141.54M | $516.04M | $356.7K |
| Return on year-end equity | n/a | 10.6% | 11.3% | n/m |
| Shares outstanding | 8.06M | 38.02M | 83.37M | 8.88M |
Revenue, most recent five fiscal years
| Fiscal year | Cryo Cell International Inc | Viemed Healthcare, Inc. | Progyny, Inc. | BioRestorative Therapies, Inc. |
|---|---|---|---|---|
| Latest | $31.57M Ended 2025-11-30 | $270.28M Ended 2025-12-31 | $1.29B Ended 2025-12-31 | $359.7K Ended 2025-12-31 |
| 1 year earlier | $31.99M Ended 2024-11-30 | $224.26M Ended 2024-12-31 | $1.17B Ended 2024-12-31 | $401.0K Ended 2024-12-31 |
| 2 years earlier | $31.34M Ended 2023-11-30 | $183.01M Ended 2023-12-31 | $1.09B Ended 2023-12-31 | $145.8K Ended 2023-12-31 |
| 3 years earlier | $30.34M Ended 2022-11-30 | $138.83M Ended 2022-12-31 | $786.91M Ended 2022-12-31 | $119.8K Ended 2022-12-31 |
| 4 years earlier | $28.88M Ended 2021-11-30 | $117.06M Ended 2021-12-31 | $500.62M Ended 2021-12-31 | $46.0K Ended 2021-12-31 |